Trials / Terminated
TerminatedNCT02666599
Per-operating Use of a Probe for Detection of β+
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- University of Lausanne Hospitals · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the sensibility of the probe Forimtech to detect β+ emission in vivo in humans and its usefulness during elective surgical procedure Hypothesis:The probe Forimtech is able to allow per-surgery detection of tumoral lesions sensible to 18F-FDG and to help in the realization of guided biopsies, minimally invasive surgery or complement of resection of tumors. The β+ emission detected by the probe Forimtech is correlated to the emission γ detected by the 18F-FDG.PET/CT
Detailed description
Patients with a malignant neoplasic lesion known or suspected for which a surgery is planned will be presented with the protocol. If inclusion/exclusion criteria are fulfilled all the procedures will be planned. A 18F-FDG PET/CT will be done. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen during the PET/CT will be detected with the probe. Resected pieces will be analysed histologically.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | 18F-FDG PET/CT | A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe. Resected pieces will be analysed histologically. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2024-03-01
- Completion
- 2024-03-30
- First posted
- 2016-01-28
- Last updated
- 2024-06-20
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02666599. Inclusion in this directory is not an endorsement.